Pediatricians’ Attitudes and Knowledge of RSV Immunization Products Article Swipe
Costanza Di Chiara
,
Pierre‐Philippe Piché‐Renaud
,
Vera Rigamonti
,
Anna Cantarutti
,
Cristina Calvo
,
Irene Rivero‐Calle
,
Antoni Soriano‐Arandes
,
Carlo Giaquinto
,
Luigi Cantarutti
,
Daniele Donà
,
Andrea Lo Vecchio
,
Adamos Hadjipanayis
,
Zoi Dorothea Pana
,
Ioannis Kopsidas
,
A. G. Rose
,
Alfredo Tagarro
,
Shaun K. Morris
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1101/2025.05.22.25328182
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1101/2025.05.22.25328182
Purpose Nirsevimab and the maternal vaccination in pregnancy are newly introduced prevention strategies against respiratory syncytial virus (RSV). This study evaluated pediatricians’ knowledge, attitudes, and barriers to RSV immunization in Italy and Cyprus/Greece, where nirsevimab had not yet been implemented, and in Spain, where it was introduced in 2023/2024. Methods A survey was distributed to pediatricians across Spain, Italy, and Cyprus/Greece in July-August/2024. Occupational characteristics, and knowledge, attitudes and practices toward palivizumab, nirsevimab, and the maternal vaccine were collected. Of 578 respondents (response rate=19.3%), 50% were from Spain, 40% from Italy, and 10% from Cyprus/Greece. As 90% of responses came from Spain and Italy, the main analysis focused on these two countries. Descriptive and univariate analyses (Chi-square or Fisher’s exact tests) were conducted. Results Respondents included pediatricians from community (51.7%), tertiary (30.4%), and primary/secondary care (17.9%) settings. Pediatricians were generally aware of RSV risk factors, without differences across countries. However, 245 (55.9%) and 375 (86.0%) participants reported average-to-low knowledge of nirsevimab and the maternal vaccine, respectively, with differences across countries (p=0.002). Despite limited knowledge, 311 (85.9%) pediatricians were willing to administer nirsevimab, and 319 (92.2%) supported its use for all infants. Nirsevimab administration’s barriers, including unfamiliarity and logistical challenges, were cited by 69 (20.0%) pediatricians. Regarding immunization preferences, 165 (47.4%) pediatricians were very likely to support the maternal vaccine over nirsevimab. Conclusions While pediatricians support RSV immunization, knowledge gaps and logistical barriers may hinder early-stage implementation. Optimizing education on RSV immunization will be crucial to improve uptake and prevention strategies. What’s Known on This Subject There is limited evidence regarding pediatricians’ attitudes and knowledge of nirsevimab and maternal RSV vaccination during pregnancy. What This Study Adds This multi-country survey evaluates pediatricians’ knowledge, attitudes, and barriers to RSV immunization in Italy and Cyprus/Greece, where nirsevimab had not yet been implemented, and in Spain, where it was introduced in 2023/2024.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1101/2025.05.22.25328182
- https://www.medrxiv.org/content/medrxiv/early/2025/05/23/2025.05.22.25328182.full.pdf
- OA Status
- green
- References
- 33
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4410635630
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4410635630Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1101/2025.05.22.25328182Digital Object Identifier
- Title
-
Pediatricians’ Attitudes and Knowledge of RSV Immunization ProductsWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-05-23Full publication date if available
- Authors
-
Costanza Di Chiara, Pierre‐Philippe Piché‐Renaud, Vera Rigamonti, Anna Cantarutti, Cristina Calvo, Irene Rivero‐Calle, Antoni Soriano‐Arandes, Carlo Giaquinto, Luigi Cantarutti, Daniele Donà, Andrea Lo Vecchio, Adamos Hadjipanayis, Zoi Dorothea Pana, Ioannis Kopsidas, A. G. Rose, Alfredo Tagarro, Shaun K. MorrisList of authors in order
- Landing page
-
https://doi.org/10.1101/2025.05.22.25328182Publisher landing page
- PDF URL
-
https://www.medrxiv.org/content/medrxiv/early/2025/05/23/2025.05.22.25328182.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.medrxiv.org/content/medrxiv/early/2025/05/23/2025.05.22.25328182.full.pdfDirect OA link when available
- Concepts
-
Immunization, Virology, Medicine, Business, Immunology, AntibodyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
33Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4410635630 |
|---|---|
| doi | https://doi.org/10.1101/2025.05.22.25328182 |
| ids.doi | https://doi.org/10.1101/2025.05.22.25328182 |
| ids.openalex | https://openalex.org/W4410635630 |
| fwci | 0.0 |
| type | preprint |
| title | Pediatricians’ Attitudes and Knowledge of RSV Immunization Products |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10976 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9801999926567078 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | Viral gastroenteritis research and epidemiology |
| topics[1].id | https://openalex.org/T10833 |
| topics[1].field.id | https://openalex.org/fields/33 |
| topics[1].field.display_name | Social Sciences |
| topics[1].score | 0.9713000059127808 |
| topics[1].domain.id | https://openalex.org/domains/2 |
| topics[1].domain.display_name | Social Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/3306 |
| topics[1].subfield.display_name | Health |
| topics[1].display_name | Vaccine Coverage and Hesitancy |
| topics[2].id | https://openalex.org/T12025 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9484000205993652 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2721 |
| topics[2].subfield.display_name | Hepatology |
| topics[2].display_name | Hepatitis Viruses Studies and Epidemiology |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780801004 |
| concepts[0].level | 3 |
| concepts[0].score | 0.7873690724372864 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1415366 |
| concepts[0].display_name | Immunization |
| concepts[1].id | https://openalex.org/C159047783 |
| concepts[1].level | 1 |
| concepts[1].score | 0.421970933675766 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[1].display_name | Virology |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.361228346824646 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C144133560 |
| concepts[3].level | 0 |
| concepts[3].score | 0.32711872458457947 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q4830453 |
| concepts[3].display_name | Business |
| concepts[4].id | https://openalex.org/C203014093 |
| concepts[4].level | 1 |
| concepts[4].score | 0.2338763177394867 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[4].display_name | Immunology |
| concepts[5].id | https://openalex.org/C159654299 |
| concepts[5].level | 2 |
| concepts[5].score | 0.08743861317634583 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[5].display_name | Antibody |
| keywords[0].id | https://openalex.org/keywords/immunization |
| keywords[0].score | 0.7873690724372864 |
| keywords[0].display_name | Immunization |
| keywords[1].id | https://openalex.org/keywords/virology |
| keywords[1].score | 0.421970933675766 |
| keywords[1].display_name | Virology |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.361228346824646 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/business |
| keywords[3].score | 0.32711872458457947 |
| keywords[3].display_name | Business |
| keywords[4].id | https://openalex.org/keywords/immunology |
| keywords[4].score | 0.2338763177394867 |
| keywords[4].display_name | Immunology |
| keywords[5].id | https://openalex.org/keywords/antibody |
| keywords[5].score | 0.08743861317634583 |
| keywords[5].display_name | Antibody |
| language | en |
| locations[0].id | doi:10.1101/2025.05.22.25328182 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306402567 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| locations[0].source.host_organization | https://openalex.org/I2750212522 |
| locations[0].source.host_organization_name | Cold Spring Harbor Laboratory |
| locations[0].source.host_organization_lineage | https://openalex.org/I2750212522 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | https://www.medrxiv.org/content/medrxiv/early/2025/05/23/2025.05.22.25328182.full.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1101/2025.05.22.25328182 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5050363285 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3586-0612 |
| authorships[0].author.display_name | Costanza Di Chiara |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Costanza Di Chiara |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5042947942 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4632-6877 |
| authorships[1].author.display_name | Pierre‐Philippe Piché‐Renaud |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Pierre-Philippe Piche-Renaud |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5027356355 |
| authorships[2].author.orcid | https://orcid.org/0009-0000-5657-4589 |
| authorships[2].author.display_name | Vera Rigamonti |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Vera Rigamonti |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5042609095 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-3700-780X |
| authorships[3].author.display_name | Anna Cantarutti |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Anna Cantarutti |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5048401594 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Cristina Calvo |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Cristina Calvo |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5072981485 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-3678-9264 |
| authorships[5].author.display_name | Irene Rivero‐Calle |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Irene Rivero Calle |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5042505216 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-9613-7228 |
| authorships[6].author.display_name | Antoni Soriano‐Arandes |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Antoni Soriano-Arandes |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5042594419 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-9365-0413 |
| authorships[7].author.display_name | Carlo Giaquinto |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Carlo Giaquinto |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5004774014 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-5514-4085 |
| authorships[8].author.display_name | Luigi Cantarutti |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Luigi Cantarutti |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5021951574 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-7105-2105 |
| authorships[9].author.display_name | Daniele Donà |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Daniele Dona |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5083855260 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-4181-6842 |
| authorships[10].author.display_name | Andrea Lo Vecchio |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Andrea Lo Vecchio |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5079469979 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-4337-3176 |
| authorships[11].author.display_name | Adamos Hadjipanayis |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Adamos Hadjipanayis |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5008877337 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-5893-1081 |
| authorships[12].author.display_name | Zoi Dorothea Pana |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Zoi Dorothea Pana |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5044179986 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-6499-4807 |
| authorships[13].author.display_name | Ioannis Kopsidas |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Ioannis Kopsidas |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5012889164 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | A. G. Rose |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Adria Rose |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5059535736 |
| authorships[15].author.orcid | https://orcid.org/0000-0003-2860-3455 |
| authorships[15].author.display_name | Alfredo Tagarro |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Alfredo Tagarro |
| authorships[15].is_corresponding | False |
| authorships[16].author.id | https://openalex.org/A5005916952 |
| authorships[16].author.orcid | https://orcid.org/0000-0001-9809-0822 |
| authorships[16].author.display_name | Shaun K. Morris |
| authorships[16].author_position | last |
| authorships[16].raw_author_name | Shaun K Morris |
| authorships[16].is_corresponding | False |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.medrxiv.org/content/medrxiv/early/2025/05/23/2025.05.22.25328182.full.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Pediatricians’ Attitudes and Knowledge of RSV Immunization Products |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10976 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9801999926567078 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | Viral gastroenteritis research and epidemiology |
| related_works | https://openalex.org/W4391375266, https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1101/2025.05.22.25328182 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306402567 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| best_oa_location.source.host_organization | https://openalex.org/I2750212522 |
| best_oa_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | https://www.medrxiv.org/content/medrxiv/early/2025/05/23/2025.05.22.25328182.full.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1101/2025.05.22.25328182 |
| primary_location.id | doi:10.1101/2025.05.22.25328182 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306402567 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| primary_location.source.host_organization | https://openalex.org/I2750212522 |
| primary_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| primary_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | https://www.medrxiv.org/content/medrxiv/early/2025/05/23/2025.05.22.25328182.full.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1101/2025.05.22.25328182 |
| publication_date | 2025-05-23 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2727509207, https://openalex.org/W4239909494, https://openalex.org/W2101114010, https://openalex.org/W2943343204, https://openalex.org/W2625910786, https://openalex.org/W4214852692, https://openalex.org/W4243457518, https://openalex.org/W4399485890, https://openalex.org/W4391683735, https://openalex.org/W4398244578, https://openalex.org/W4401931783, https://openalex.org/W4400919992, https://openalex.org/W4405721600, https://openalex.org/W4402467886, https://openalex.org/W4403092831, https://openalex.org/W4405185563, https://openalex.org/W4362636468, https://openalex.org/W3214805817, https://openalex.org/W2909323993, https://openalex.org/W2127516664, https://openalex.org/W2063713720, https://openalex.org/W2075410325, https://openalex.org/W4392160088, https://openalex.org/W4390889253, https://openalex.org/W4321456701, https://openalex.org/W4402861548, https://openalex.org/W4390011058, https://openalex.org/W4404361529, https://openalex.org/W3214690249, https://openalex.org/W4389481808, https://openalex.org/W4389373185, https://openalex.org/W3042680521, https://openalex.org/W4321768432 |
| referenced_works_count | 33 |
| abstract_inverted_index.A | 51 |
| abstract_inverted_index.69 | 203 |
| abstract_inverted_index.As | 96 |
| abstract_inverted_index.Of | 80 |
| abstract_inverted_index.be | 243 |
| abstract_inverted_index.by | 202 |
| abstract_inverted_index.in | 7, 30, 42, 48, 62, 289, 301, 307 |
| abstract_inverted_index.is | 257 |
| abstract_inverted_index.it | 45, 304 |
| abstract_inverted_index.of | 98, 142, 160, 265 |
| abstract_inverted_index.on | 109, 239, 253 |
| abstract_inverted_index.or | 118 |
| abstract_inverted_index.to | 27, 55, 180, 215, 245, 286 |
| abstract_inverted_index.10% | 93 |
| abstract_inverted_index.165 | 209 |
| abstract_inverted_index.245 | 151 |
| abstract_inverted_index.311 | 175 |
| abstract_inverted_index.319 | 184 |
| abstract_inverted_index.375 | 154 |
| abstract_inverted_index.40% | 89 |
| abstract_inverted_index.50% | 85 |
| abstract_inverted_index.578 | 81 |
| abstract_inverted_index.90% | 97 |
| abstract_inverted_index.RSV | 28, 143, 226, 240, 269, 287 |
| abstract_inverted_index.all | 190 |
| abstract_inverted_index.and | 3, 25, 32, 41, 60, 66, 69, 74, 92, 103, 114, 133, 153, 162, 183, 197, 230, 248, 263, 267, 284, 291, 300 |
| abstract_inverted_index.are | 9 |
| abstract_inverted_index.for | 189 |
| abstract_inverted_index.had | 36, 295 |
| abstract_inverted_index.its | 187 |
| abstract_inverted_index.may | 233 |
| abstract_inverted_index.not | 37, 296 |
| abstract_inverted_index.the | 4, 75, 105, 163, 217 |
| abstract_inverted_index.two | 111 |
| abstract_inverted_index.use | 188 |
| abstract_inverted_index.was | 46, 53, 305 |
| abstract_inverted_index.yet | 38, 297 |
| abstract_inverted_index.Adds | 276 |
| abstract_inverted_index.This | 19, 254, 274, 277 |
| abstract_inverted_index.What | 273 |
| abstract_inverted_index.been | 39, 298 |
| abstract_inverted_index.came | 100 |
| abstract_inverted_index.care | 135 |
| abstract_inverted_index.from | 87, 90, 94, 101, 128 |
| abstract_inverted_index.gaps | 229 |
| abstract_inverted_index.main | 106 |
| abstract_inverted_index.over | 220 |
| abstract_inverted_index.risk | 144 |
| abstract_inverted_index.very | 213 |
| abstract_inverted_index.were | 78, 86, 122, 139, 178, 200, 212 |
| abstract_inverted_index.will | 242 |
| abstract_inverted_index.with | 167 |
| abstract_inverted_index.Italy | 31, 290 |
| abstract_inverted_index.Known | 252 |
| abstract_inverted_index.Spain | 102 |
| abstract_inverted_index.Study | 275 |
| abstract_inverted_index.There | 256 |
| abstract_inverted_index.While | 223 |
| abstract_inverted_index.aware | 141 |
| abstract_inverted_index.cited | 201 |
| abstract_inverted_index.exact | 120 |
| abstract_inverted_index.newly | 10 |
| abstract_inverted_index.study | 20 |
| abstract_inverted_index.these | 110 |
| abstract_inverted_index.virus | 17 |
| abstract_inverted_index.where | 34, 44, 293, 303 |
| abstract_inverted_index.(RSV). | 18 |
| abstract_inverted_index.Italy, | 59, 91, 104 |
| abstract_inverted_index.Spain, | 43, 58, 88, 302 |
| abstract_inverted_index.across | 57, 148, 169 |
| abstract_inverted_index.during | 271 |
| abstract_inverted_index.hinder | 234 |
| abstract_inverted_index.likely | 214 |
| abstract_inverted_index.survey | 52, 279 |
| abstract_inverted_index.tests) | 121 |
| abstract_inverted_index.toward | 71 |
| abstract_inverted_index.uptake | 247 |
| abstract_inverted_index.(17.9%) | 136 |
| abstract_inverted_index.(20.0%) | 204 |
| abstract_inverted_index.(47.4%) | 210 |
| abstract_inverted_index.(55.9%) | 152 |
| abstract_inverted_index.(85.9%) | 176 |
| abstract_inverted_index.(86.0%) | 155 |
| abstract_inverted_index.(92.2%) | 185 |
| abstract_inverted_index.Despite | 172 |
| abstract_inverted_index.Methods | 50 |
| abstract_inverted_index.Purpose | 1 |
| abstract_inverted_index.Results | 124 |
| abstract_inverted_index.Subject | 255 |
| abstract_inverted_index.against | 14 |
| abstract_inverted_index.crucial | 244 |
| abstract_inverted_index.focused | 108 |
| abstract_inverted_index.improve | 246 |
| abstract_inverted_index.limited | 173, 258 |
| abstract_inverted_index.support | 216, 225 |
| abstract_inverted_index.vaccine | 77, 219 |
| abstract_inverted_index.willing | 179 |
| abstract_inverted_index.without | 146 |
| abstract_inverted_index.(30.4%), | 132 |
| abstract_inverted_index.(51.7%), | 130 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.However, | 150 |
| abstract_inverted_index.What’s | 251 |
| abstract_inverted_index.analyses | 116 |
| abstract_inverted_index.analysis | 107 |
| abstract_inverted_index.barriers | 26, 232, 285 |
| abstract_inverted_index.evidence | 259 |
| abstract_inverted_index.factors, | 145 |
| abstract_inverted_index.included | 126 |
| abstract_inverted_index.infants. | 191 |
| abstract_inverted_index.maternal | 5, 76, 164, 218, 268 |
| abstract_inverted_index.reported | 157 |
| abstract_inverted_index.tertiary | 131 |
| abstract_inverted_index.vaccine, | 165 |
| abstract_inverted_index.(response | 83 |
| abstract_inverted_index.Regarding | 206 |
| abstract_inverted_index.attitudes | 68, 262 |
| abstract_inverted_index.barriers, | 194 |
| abstract_inverted_index.community | 129 |
| abstract_inverted_index.countries | 170 |
| abstract_inverted_index.education | 238 |
| abstract_inverted_index.evaluated | 21 |
| abstract_inverted_index.evaluates | 280 |
| abstract_inverted_index.generally | 140 |
| abstract_inverted_index.including | 195 |
| abstract_inverted_index.knowledge | 159, 228, 264 |
| abstract_inverted_index.practices | 70 |
| abstract_inverted_index.pregnancy | 8 |
| abstract_inverted_index.regarding | 260 |
| abstract_inverted_index.responses | 99 |
| abstract_inverted_index.settings. | 137 |
| abstract_inverted_index.supported | 186 |
| abstract_inverted_index.syncytial | 16 |
| abstract_inverted_index.(p=0.002). | 171 |
| abstract_inverted_index.2023/2024. | 49, 308 |
| abstract_inverted_index.Fisher’s | 119 |
| abstract_inverted_index.Nirsevimab | 2, 192 |
| abstract_inverted_index.Optimizing | 237 |
| abstract_inverted_index.administer | 181 |
| abstract_inverted_index.attitudes, | 24, 283 |
| abstract_inverted_index.collected. | 79 |
| abstract_inverted_index.conducted. | 123 |
| abstract_inverted_index.countries. | 112, 149 |
| abstract_inverted_index.introduced | 11, 47, 306 |
| abstract_inverted_index.knowledge, | 23, 67, 174, 282 |
| abstract_inverted_index.logistical | 198, 231 |
| abstract_inverted_index.nirsevimab | 35, 161, 266, 294 |
| abstract_inverted_index.pregnancy. | 272 |
| abstract_inverted_index.prevention | 12, 249 |
| abstract_inverted_index.strategies | 13 |
| abstract_inverted_index.univariate | 115 |
| abstract_inverted_index.(Chi-square | 117 |
| abstract_inverted_index.Conclusions | 222 |
| abstract_inverted_index.Descriptive | 113 |
| abstract_inverted_index.Respondents | 125 |
| abstract_inverted_index.challenges, | 199 |
| abstract_inverted_index.differences | 147, 168 |
| abstract_inverted_index.distributed | 54 |
| abstract_inverted_index.early-stage | 235 |
| abstract_inverted_index.nirsevimab, | 73, 182 |
| abstract_inverted_index.nirsevimab. | 221 |
| abstract_inverted_index.respiratory | 15 |
| abstract_inverted_index.respondents | 82 |
| abstract_inverted_index.strategies. | 250 |
| abstract_inverted_index.vaccination | 6, 270 |
| abstract_inverted_index.Occupational | 64 |
| abstract_inverted_index.immunization | 29, 207, 241, 288 |
| abstract_inverted_index.implemented, | 40, 299 |
| abstract_inverted_index.palivizumab, | 72 |
| abstract_inverted_index.participants | 156 |
| abstract_inverted_index.preferences, | 208 |
| abstract_inverted_index.rate=19.3%), | 84 |
| abstract_inverted_index.Cyprus/Greece | 61 |
| abstract_inverted_index.Pediatricians | 138 |
| abstract_inverted_index.immunization, | 227 |
| abstract_inverted_index.multi-country | 278 |
| abstract_inverted_index.pediatricians | 56, 127, 177, 211, 224 |
| abstract_inverted_index.respectively, | 166 |
| abstract_inverted_index.unfamiliarity | 196 |
| abstract_inverted_index.Cyprus/Greece, | 33, 292 |
| abstract_inverted_index.Cyprus/Greece. | 95 |
| abstract_inverted_index.average-to-low | 158 |
| abstract_inverted_index.pediatricians. | 205 |
| abstract_inverted_index.implementation. | 236 |
| abstract_inverted_index.characteristics, | 65 |
| abstract_inverted_index.pediatricians’ | 22, 261, 281 |
| abstract_inverted_index.July-August/2024. | 63 |
| abstract_inverted_index.primary/secondary | 134 |
| abstract_inverted_index.administration’s | 193 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 17 |
| citation_normalized_percentile.value | 0.247397 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |